Jean-Philippe Brosseau

Financement

• Subvention. Contribution of Alternative Splicing to Neurofibromagenesis. Congressionally Directed Medical Research Programs (Frederick, États-Unis). 485 597 USD. (2024-2027).
  Numéro de subvention : HT9425-24-1-0482. Voir plus
• Subvention. Contribution de l`épissage alternatif dans le développement de neurofibrome. Fonds de Recherche du Québec - Santé (Montreal, Canada). 303 086 $. (2024-2028).
  Numéro de subvention : 348951. Voir plus
• Subvention. Tumor-Associated Fibroblasts Impairing Malignant Progression. Canadian Institutes of Health Research (Ottawa, Canada). 123 000 $. (2023-2024).
  Numéro de subvention : 202209DCP. Voir plus
• Subvention. Development of NF1 Gene Therapy. Canadian Institutes of Health Research (Ottawa, Canada). 60 000 $. (2022-2024).
  Numéro de subvention : 202202CR4. Voir plus
• Subvention. Deciphering the alternative splicing regulatory program driving the myofibroblast state. Natural Sciences and Engineering Research Council (Ottawa, Canada). 30 000 $. (2022-2023).
  Numéro de subvention : RGPIN-2021-04035. Voir plus
• Subvention. Deciphering the alternative splicing regulatory program driving the myofibroblast state. Natural Sciences and Engineering Research Council (Ottawa, Canada). 12 500 $. (2021-2022).
  Numéro de subvention : DGECR-2021-00282. Voir plus
• Subvention. Fonction et régulation d'une matrice extracellulaire spécifique qui promouvoit la formation de neurofibrome. Fonds de Recherche du Québec - Santé (Montreal, Canada). 80 000 $. (2020-2024).
  Numéro de subvention : 295641. Voir plus
• Subvention. No title. Fonds de Recherche du Québec - Santé (Montreal, Canada). 17 500 $. (2020-2021).
  Numéro de subvention : 309162. Voir plus
• Subvention. Fonction et régulation d'une matrice extracellulaire spécifique qui promouvoit la formation de neurofibrome. Fonds de Recherche du Québec - Santé (Montreal, Canada). 267 401 $. (2020-2024).
  Numéro de subvention : 281660. Voir plus
• Subvention. The NF1 Microenvironment: Friend or Foe?. Congressionally Directed Medical Research Programs (Frederick, États-Unis). 324 000 USD. (2019-2023).
  Numéro de subvention : W81XWH-19-1-0238. Voir plus

Publications

Articles

• Alli-Oke O, Bergeron D, Kessai F, Thibault P, Durand M, Brosseau JP. (2026). Splicing isoforms associated with TGFβ-induced myofibroblast activation. BMC molecular and cell biology. DOI
• Hewa Bostanthirige D, Plante C, Caron M, Gascon S, Lévesque M, Poirier C, Deschenes M, Sabo Vatasescu JP, Chabot B, Geha S, Laurent B, Brosseau JP. (2026). Proof-of-principle of NF1 gene therapy in plexiform neurofibroma xenograft mouse models. Communications biology. DOI
• ElChoueiry M, Sidhu H, Lévesque M, Lévesque D, Jacques JF, Sarrhini O, Beaudoin JF, Caron M, Gaudette B, Lecomte R, Roucou X, Boisvert FM, Brosseau JP. (2025). Development, validation, and preliminary phenotypic characterization of a Col6a3 knockout mouse model targeting exon 3. Animal models and experimental medicine. DOI
• Opeoluwa Alli-Oke, Jean-Philippe Brosseau. (2025). Best evidence linking the extracellular factor TGF-β to cancer-associated alternative splicing programs. BBA Advances. DOI
• Eve Petit, Viktoriia Bavykina, Martin Thibault, André Bilodeau, William Choinière, Jean-Philippe Brosseau, Benoit Laurent, Marc-Antoine Lauzon. (2024). Assessing tissue mechanical properties: Development of a custom-made tensile device and application on rodents sciatic nerves. Journal of the Mechanical Behavior of Biomedical Materials. DOI
• Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, Jean-Philippe Brosseau. (2024). Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma. PLOS ONE. DOI
• Deng S, Zhang Y, Wang H, Liang W, Xie L, Li N, Fang Y, Wang Y, Liu J, Chi H, Sun Y, Ye R, Shan L, Shi J, Shen Z, Wang S, Brosseau JP, Wang F, Liu G, ... Xu J. (2024). ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion. Cell. DOI
• Rhéaume K, Chen Z, Wang Y, Plante C, Hewa Bostanthirige D, Lévesque M, Geha S, Le LQ, Brosseau JP. (2023). Whole Central and Peripheral Nervous System Mice Dissection. Journal of visualized experiments : JoVE. DOI
• Teddy Mohamad, Camille Plante, Jean-Philippe Brosseau. (2021). Toward Understanding the Mechanisms of Malignant Peripheral Nerve Sheath Tumor Development. International Journal of Molecular Sciences. DOI
• Brosseau JP, Sathe AA, Wang Y, Nguyen T, Glass DA 2nd, Xing C, Le LQ. (2021). Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing. Acta neuropathologica communications. DOI
• Yao H, Li C, He F, Song T, Brosseau JP, Wang H, Lu H, Fang C, Shi H, Lan J, Fang JY, Xu J. (2020). A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions. RSC chemical biology. DOI
• Chen Z, Li S, Mo J, Hawley E, Wang Y, He Y, Brosseau JP, Shipman T, Clapp DW, Carroll TJ, Le LQ. (2020). Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling. JCI insight. DOI
• Xu J, Brosseau JP, Shi H. (2020). Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy. Oncogene. DOI
• Brosseau JP, Liao CP, Le LQ. (2020). Translating current basic research into future therapies for neurofibromatosis type 1. British journal of cancer. DOI
• Brosseau JP. (2020). Regulations on Messenger RNA: Wires and Nodes. Advances in experimental medicine and biology. DOI
• Brosseau JP, Le LQ. (2019). Heterozygous Tumor Suppressor Microenvironment in Cancer Development. Trends in cancer. DOI
• Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, Lu H, Fang C, Zhang Y, Liang L, Zhou X, Wang C, Xue Y, Cui Y, Xu J. (2019). Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nature biomedical engineering. DOI
• Jean-Philippe Brosseau. (2018). Splicing isoform-specific functional genomic in cancer cells. Applied Cancer Research. DOI
• Brosseau JP, Liao CP, Wang Y, Ramani V, Vandergriff T, Lee M, Patel A, Ariizumi K, Le LQ. (2018). NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. Nature communications. DOI
• Chen Z, Mo J, Brosseau JP, Shipman T, Wang Y, Liao CP, Cooper JM, Allaway RJ, Gosline SJC, Guinney J, Carroll TJ, Le LQ. (2018). Spatiotemporal Loss of <i>NF1</i> in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway. Cancer discovery. DOI
• Brosseau JP, Pichard DC, Legius EH, Wolkenstein P, Lavker RM, Blakeley JO, Riccardi VM, Verma SK, Brownell I, Le LQ. (2018). The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities. Neurology. DOI
• Liao CP, Booker RC, Brosseau JP, Chen Z, Mo J, Tchegnon E, Wang Y, Clapp DW, Le LQ. (2018). Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis. The Journal of clinical investigation. DOI
• Brosseau JP, Lucier JF, Lamarche AA, Shkreta L, Gendron D, Lapointe E, Thibault P, Paquet E, Perreault JP, Abou Elela S, Chabot B. (2013). Redirecting splicing with bifunctional oligonucleotides. Nucleic acids research. DOI
• Brosseau JP, Lucier JF, Nwilati H, Thibault P, Garneau D, Gendron D, Durand M, Couture S, Lapointe E, Prinos P, Klinck R, Perreault JP, Chabot B, Abou-Elela S. (2013). Tumor microenvironment-associated modifications of alternative splicing. RNA (New York, N.Y.). DOI
• Lecka J, Gillerman I, Fausther M, Salem M, Munkonda MN, Brosseau JP, Cadot C, Martín-Satué M, d'Orléans-Juste P, Rousseau E, Poirier D, Künzli B, Fischer B, Sévigny J. (2013). 8-BuS-ATP derivatives as specific NTPDase1 inhibitors. British journal of pharmacology. DOI
• Venables JP, Brosseau JP, Gadea G, Klinck R, Prinos P, Beaulieu JF, Lapointe E, Durand M, Thibault P, Tremblay K, Rousset F, Tazi J, Abou Elela S, Chabot B. (2012). RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Molecular and cellular biology. DOI
• Prinos P, Garneau D, Lucier JF, Gendron D, Couture S, Boivin M, Brosseau JP, Lapointe E, Thibault P, Durand M, Tremblay K, Gervais-Bird J, Nwilati H, Klinck R, Chabot B, Perreault JP, Wellinger RJ, Elela SA. (2011). Alternative splicing of SYK regulates mitosis and cell survival. Nature structural & molecular biology. DOI
• Brosseau JP, Lucier JF, Lapointe E, Durand M, Gendron D, Gervais-Bird J, Tremblay K, Perreault JP, Elela SA. (2009). High-throughput quantification of splicing isoforms. RNA (New York, N.Y.). DOI
• Brosseau JP, Neugebauer WA, Gobeil F Jr, D'Orléans-Juste P. (2009). Design, synthesis and pharmacological characterization of fluorescein-derived endothelin antagonists Bq-123 and Bq-788. Advances in experimental medicine and biology. DOI
• Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C, Gervais-Bird J, Lapointe E, Froehlich U, Durand M, Gendron D, Brosseau JP, Thibault P, Lucier JF, Tremblay K, Prinos P, Wellinger RJ, Chabot B, Rancourt C, Elela SA. (2008). Identification of alternative splicing markers for breast cancer. Cancer research. DOI
• Brosseau JP, D'Orléans-Juste P, Neugebauer WA. (2005). Development of an efficient strategy for the synthesis of the ETB receptor antagonist BQ-788 and some related analogues. Peptides. DOI

Autres contributions

Cours enseignés ou supervisés à l'UdeS

• BCM525 - Biomolécules : caractérisation et applications. (2024-2026). (2CR).
• BCM624 - Initiation à une technique biochimique. (2023-2026). (1CR).
• BCM625 - Recherche en biochimie de la santé. (2023-2026). (2CR).
• BCM626 - Recherche en biochimie médicale. (2023-2026). (2CR).
• BCM627 - Projet expérimental en biochimie de la santé. (2023-2026). (3CR).
• BCM628 - Projet de recherche en biochimie de la santé. (2023-2026). (4CR).
• EFD904 - Rédiger et publier un article scientifique. (2024-2026). (4CR).
• BCM502 - Biomolécules : caractérisation et applications. (2023). (3CR).